This paper studies the effectiveness and safety of narrowband UV-B (NBUVB) phototherapy for treating moderate to severe atopic dermatitis in children. It was a prospective clinical trial that followed patients for 2 years after treatment to assess both short and long-term effects.

The study included 30 children aged 4-14 years with moderate to severe atopic dermatitis. 90% had moderate disease (SCORAD 25-50) and 10% had severe disease (SCORAD >50). All patients were of Indian origin and had failed to respond adequately to topical treatments alone.

90% of patients showed clearance of their disease, with most achieving clearance by the 18th treatment session. The SCORAD index decreased significantly from 30.42 at baseline to 7.82 at the end of treatment. Patients also showed significant improvements in itching and sleep. The improvements were maintained during the 2-year follow-up period, though there was some gradual decline in effect. Side effects were mild and included temporary redness in some patients.

The authors concluded that NBUVB phototherapy is both safe and effective for treating moderate to severe atopic dermatitis in children. They suggest it could be considered as a first-line therapy before moving to more toxic treatments, given its good therapeutic benefits and low side effect profile. However, they note that longer studies are needed to fully assess any potential long-term cancer risks.